Nov.16 — Moderna Inc. reported its Covid-19 vaccine was 94.5% effective in a preliminary analysis of a large late-stage clinical trial. Noubar Afeyan, Moderna co-founder and chairman, discusses the company’s new data, distribution, plan for emergency use authorization and its advantage over a vaccine by Pfizer Inc. Afeyan spoke with Bloomberg’s Emily Chang.
source
Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.
This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.